I-SPY COVID-19 (NCT04488081) is a phase 2, multi-centre, open-label, platform clinical trial designed by Quantum Leap Healthcare Collaborative™ to rapidly evaluate repurposed and investigational agents in critically ill patients infected with SARS-CoV-2. In this interview, we speak with Prof. Angela Haczku (University of California at Davis, CA, USA), one of the study investigators for the cyclosporine arm of the study. Cyclosporine is a frequently prescribed immunosuppressant that was hypothesized to be of potential benefit in critically ill patients with COVID-19 due to its possible ability to suppress the ‘cytokine storm’ and hence reduce the chance of COVID-19-related lung injury. However, the testing of cyclosporine in I-SPY COVID-19 was recently discontinued when the drug failed to meet the pre-defined primary outcome criteria. In this interview, we discuss the trial and its results in more detail.
- What is the rationale for the use of cyclosporine in patients hospitalized with COVID-19? (0:17)
- What were the aims and design of the I-SPY COVID trial? (0:58)
- Why was the cyclosporine arm terminated? (3:05)
- What factors might have contributed to this disappointing finding, and what questions remain unanswered? (4:14)
- What are the future goals for the I-SPY study? (6:36)
Disclosures: Angela Haczku has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!